[Current aspects of the therapy of uremic hyperphosphatemia].
Schaefer
K
K
Medizinische Abteilung II, St.-Joseph-Krankenhaus I, Berlin.
von Herrath
D
D
Erley
C M
CM
D000464:Alginates / Q000627:therapeutic use; D000596:Amino Acids / Q000627:therapeutic use; D002119:Calcium Carbonate / Q000627:therapeutic use; D002125:Calcium Gluconate / Q000627:therapeutic use; D002951:Citrates / Q000627:therapeutic use; D019343:Citric Acid; D020723:Glucuronic Acid; D006603:Hexuronic Acids; D006801:Humans; D007651:Keto Acids / Q000627:therapeutic use; D008274:Magnesium / Q000627:therapeutic use; D008276:Magnesium Hydroxide / Q000627:therapeutic use; D010710:Phosphates / Q000097:blood*; D014511:Uremia / Q000097:blood / Q000188:drug therapy*
D000464:Alginates; D000596:Amino Acids; D002951:Citrates; D006603:Hexuronic Acids; D007651:Keto Acids; D010710:Phosphates; C005479:magnesium carbonate; D019343:Citric Acid; D020723:Glucuronic Acid; D002119:Calcium Carbonate; D008274:Magnesium; D008276:Magnesium Hydroxide; D002125:Calcium Gluconate
Aktuelle Aspekte in der Therapie der urämischen Hyperphosphatämie.